Clinical trial
Oblimersen, Cytarabine, and Daunorubicin in Treating Older Patients With Acute…
NCT00039117 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00039117 |
|---|---|
| Title | Oblimersen, Cytarabine, and Daunorubicin in Treating Older Patients With Acute Myeloid Leukemia |
| Official title | A Phase I Study of G3139 ( NSC # 683428) in Combination With Cytarabine and Daunorubicin in Previously Untreated Patients With Acute Myeloid Leukemia (AML)>= 60 Years of Age |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13, q22), Adult Acute Myeloid Leukemia With t(16, 16)(p13, Adult Acute Myeloid Leukemia With t(8, 21)(q22, Secondary Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia |
| Intervention type | Biological, Drug, Other |
| Interventions | oblimersen sodium, cytarabine, daunorubicin hydrochloride, laboratory biomarker analysis, pharmacological study |
| Enrollment | 32 |
| Start date | Apr 1, 2002 |
| Primary completion | Sep 1, 2003 |
| First posted | Jan 27, 2003 |
| Last update posted | Dec 4, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: